DOCSLIB.ORG

European Guideline on Chronic Pruritus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
European Guideline on Chronic Pruritus European Guideline on Chronic Pruritus In cooperation with the European Dermatology Forum (EDF) and the European Academy of Dermatology and Venereology (EADV) Elke Weisshaar1, Jacek C Szepietowski2, Florence Dalgard3, Simone Garcovitch4, Uwe Gieler5, Ana Gimenez-Arnau6, Julien Lambert7, Tabi Leslie8, Thomas Mettang9, Laurent Misery10, Ekin Savk11, Markus Streit12, Erwin Tschachler13, Joanna Wallengren14, Sonja Ständer15 1 Department of Clinical Social Medicine, Environmental and Occupational Dermatology, Ruprecht-Karls-University Heidelberg, Germany 2 Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Poland 3 Department of Dermatology and Venerology, Skane University Hospital, Lund University, Malmö, Sweden and National Centre for Dual Diagnosis, Innlandet Hospital Trust, Brummundal, Norway 4 Institute of Dermatology, F. Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy 5 Department of Psychosomatic Dermatology, Clinic for Psychosomatic Medicine, University of Giessen, Germany 6 Department of Dermatology, Hospital del Mar- Institut Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain 7 Department of Dermatology, University Hospital of Antwerp, University of Antwerp, Belgium 8 Department of Dermatology, Royal Free Hospital, London, UK 9 Department of Nephrology, DKD Helios Wiesbaden, Germany 10 Department of Dermatology, University Hospital Brest, France 11 Department of Dermatology, Adnan Menderes University, Aydin, Turkey 12 Department of Dermatology, Kantonsspital Aarau, Switzerland 13 Department of Dermatology, Medical University Vienna, Austria 14 Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Dermatology and Venereology, Lund, Sweden 15 Department of Dermatology, Center for Chronic Pruritus, University Hospital Muenster, Germany Corresponding authors: Sonja Ständer M.D. Center for Chronic Pruritus, Department of Dermatology University Hospital Münster Von-Esmarch-Str. 58 D-48149 Münster, Germany Tel: 0049-251-8356510 Fax: 0049-251-8352559 Email: [email protected] Elke Weisshaar M.D. Dept. Clinical Social Medicine, Occupational and Environmental Dermatology Ruprecht-Karls University Heidelberg Voßstr. 2 D-69115 Heidelberg, Germany Tel: 0049-6221-568752 Fax: 0049-6221-565584 Email: [email protected] 1 Abstract Pruritus is a frequent symptom in medicine. Population-based studies show that every 5th person in the general population has suffered from chronic pruritus (CP) at least once in the lifetime with a 12-month incidence of 7%. In patient populations its frequency is much higher depending on the underlying cause, ranging from around 25% in haemodialysis patients to 100% in skin diseases such as urticaria and atopic dermatitis (AD). Pruritus may be the result of a dermatological or non-dermatological disease. Especially in non-diseased skin it may be caused by systemic, neurological or psychiatric diseases, as well as being a side effect of medications. In a number of cases CP may be of multifactorial origin. Pruritus needs a precise diagnostic work-up. Management of CP comprises treatment of the underlying disease and topical treatment modalities, including symptomatic antipruritic treatment, ultraviolet phototherapy and systemic treatment. Treating CP needs to be targeted, multimodal and performed in a step- wise procedure requiring an interdisciplinary approach. We present the updated European guideline on chronic pruritus by a team of European pruritus experts from different disciplines. This version is an updated version of the guideline that was published in 2012 and updated in 2014 (www.euroderm.org). Conflict of Interest: see table enclosed Financial support: none Composition of the guideline group: experts in the field from Europe. More than 30% are European Academy of Dermatology and Venereology (EADV) members 2 Abbreviations and explanations AD Atopic dermatitis AEP Atopic eruption of pregnancy CGRP Calcitonin gene-related peptide CKD Chronic kidney disease CNS Central nervous system CNPG Chronic nodular prurigo CP Chronic pruritus (longer than 6 weeks) CPG Chronic prurigo CSU Chronic spontaneous urticaria DIF Direct immunofluorescence ICP Intrahepatic cholestasis of pregnancy IFSI International Forum on the Study of Itch IIF Indirect immunofluorescence IL Interleukin Itch Synonym of pruritus NRS Numerical rating scale NSAID Non-steroidal anti-inflammatory drugs PAR Proteinase-activated receptor PBC Primary biliary cirrhosis PEP Polymorphic eruption of pregnancy PG Pemphigoid gestationis Pruritus A skin sensation that elicits the urge to scratch PUO Pruritus of undetermined origin PTH Parathyroid hormone PV Polycythaemia vera RCT Randomised controlled trials SSRI Selective serotonin re-uptake inhibitors TRP Transient receptor potential UP Uremic pruritus UV Ultraviolet VAS Visual analogue scale VIP Vasoactive intestinal peptide VRS Visual rating scale 3 1 The challenge of writing this guideline ......................................................................... 5 2 Definitions and clinical classification............................................................................ 6 3 Epidemiology of chronic pruritus ................................................................................. 7 4 The clinical picture of chronic pruritus ......................................................................... 9 4.1 4.1.1 Chronic Pruritus in lesional and non-lesional skin ......................................................... 9 4.1.2 Pruritus in kidney disease .............................................................................................. 9 4.1.3 Pruritus in hepatobiliary diseases (cholestatic pruritus) .............................................. 10 4.1.4 Pruritus in metabolic and endocrine diseases ............................................................. 11 4.1.5 Pruritus in malignancy .................................................................................................. 11 4.1.6 Pruritus in infectious diseases ..................................................................................... 12 4.1.7 Pruritus in neurological diseases ................................................................................. 13 4.1.8 Pruritus in psychiatric diseases .................................................................................... 14 4.1.9 Drug-induced chronic pruritus ...................................................................................... 14 4.2 Specific patient populations ................................................................................................. 15 4.2.1 Chronic pruritus in the elderly ...................................................................................... 15 4.2.2 Chronic pruritus in pregnancy ...................................................................................... 15 4.2.3 Chronic pruritus in children .......................................................................................... 16 5 Diagnostic management ......................................................................................... 178 5.1 Patient history and clinical examination ............................................................................. 178 5.2 Diagnostic algorithm and diagnostics .................................................................................. 21 6 Therapy .................................................................................................................. 212 6.1 Therapy: general principles including emollients ............................................................... 212 6.2 Causative therapy and aetiology-specific treatment ............................................................ 23 6.3 Topical therapy .................................................................................................................... 24 6.3.1 Local anaesthetics ....................................................................................................... 24 6.3.2 Zinc, menthol and camphor ......................................................................................... 25 6.3.3 Capsaicin ..................................................................................................................... 26 6.3.4 Topical glucocorticosteroids ......................................................................................... 27 6.3.5 Tacrolimus and pimecrolimus ...................................................................................... 28 6.3.6 Acetylsalicylic acid ....................................................................................................... 29 6.3.7 Doxepin ........................................................................................................................ 30 6.3.8 Topical mast cell inhibitors ........................................................................................... 30 6.4 Systemic therapy ................................................................................................................. 30 6.4.1 Antihistamines .............................................................................................................. 30 6.4.2 Mast cell inhibitors........................................................................................................ 33 6.4.3 Glucocorticosteroids ...................................................................................................
Load more

Recommended publications
  • Rare Diseases: GI/Metabolic
    Rare Diseases: GI / Metabolic Ciara Kennedy, PhD, MBA – Head of Cholestatic Liver Disease David Piccoli, MD – Chief of Gastroenterology, Hepatology & Nutrition, Children’s Hospital Of Philadelphia Our purpose We enable people with life-altering conditions to lead better lives. The “SAFE HARBOR” Statement Under the Private Securities Litigation Reform Act of 1995 Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements can be identified by words such as “aspiration”, “will”, “expect”, “forecast”, “aspiration”, “potential”, “estimates”, “may”, “anticipate”, “target”, “project” or similar expressions suitable for identifying information that refers to future events. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that: . Shire’s products may not be a commercial success; . revenues from ADDERALL XR are subject to generic erosion and revenues from INTUNIV will become subject to generic competition starting in December 2014; . the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire's products may impact future revenues, financial condition and results of operations; . Shire conducts its own manufacturing operations for certain of its products and is reliant on third party contractors to manufacture other products and to provide goods and services. Some of Shire’s products or ingredients are only available from a single approved source for manufacture. Any disruption to the supply chain for any of Shire’s products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time.
    [Show full text]
  • Itch in Ethnic Populations
    Acta Derm Venereol 2010; 90: 227–234 REVIEW ARTICLE Itch in Ethnic Populations Hong Liang TEY1 and Gil YOSIPOVITCH2 1National Skin Centre, 1, Mandalay Road, Singapore, Singapore, and 2Department of Dermatology, Neurobiology & Anatomy, and Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, NC, USA Racial and ethnic differences in the prevalence and clini- DIFFERENCES IN SKIN BIOLOGY AND ITCH cal characteristics of itch have rarely been studied. The aim of this review is to highlight possible associations Few studies have examined the differences between between ethnicity and different forms of chronic itch. We skin types in relation to ethnicity and neurobiology of provide a current review of the prevalence of different the skin. Differences between ethnic skin types and types of itch in ethnic populations. Genetic variation may skin properties may explain racial disparities seen in significantly affect receptors for itch as well as response pruritic dermatologic disorders. to anti-pruritic therapies. Primary cutaneous amyloido- sis, a type of pruritic dermatosis, is particularly common Epidermal structure and function in Asians and rare in Caucasians and African Ameri- cans, and this may relate to a genetic polymorphism in A recent study has shown that the skin surface and the Interleukin-31 receptor. Pruritus secondary to the melanocyte cytosol of darkly pigmented skin is more use of chloroquine for malaria is a common problem for acidic compared with those of type I–III skin (1). Serine African patients, but is not commonly reported in other protease enzymes, which have significant roles as pruri- ethnic groups. In patients with primary biliary cirrho- togens in atopic eczema and other chronic skin diseases, sis, pruritus is more common and more severe in African have been shown to be significantly reduced in black Americans and Hispanics compared with Caucasians.
    [Show full text]
  • Review Article Pruritus in Systemic Diseases: a Review of Etiological Factors and New Treatment Modalities
    Hindawi Publishing Corporation e Scientific World Journal Volume 2015, Article ID 803752, 8 pages http://dx.doi.org/10.1155/2015/803752 Review Article Pruritus in Systemic Diseases: A Review of Etiological Factors and New Treatment Modalities Nagihan Tarikci, Emek Kocatürk, Fule Güngör, IlteriG OLuz Topal, Pelin Ülkümen Can, and Ralfi Singer Department of Dermatology, Okmeydanı Training and Research Hospital, 34384 Istanbul, Turkey Correspondence should be addressed to Emek Kocaturk;¨ [email protected] Received 20 February 2015; Revised 11 June 2015; Accepted 16 June 2015 Academic Editor: Uwe Wollina Copyright © 2015 Nagihan Tarikci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Pruritus is the most frequently described symptom in dermatology and can significantly impair the patient’s quality of life. In 10–50% of adults with persistent pruritus, it can be an important dermatologic clue for the presence of a significant underlying systemic disease such as renal insufficiency, cholestasis, hematologic disorder, or malignancy (Etter and Myers, 2002; Zirwas and Seraly, 2001). This review describes the presence of pruritus in different systemic diseases. It is quite important to discover the cause of pruritus for providing relief for the patients experiencing substantial morbidity caused by this condition. 1. Pruritus Endocrinal Disorders. Thyroid diseases, diabetes mellitus. Pruritus is a topic that has caused a great deal of controversy Paraneoplastic Diseases. Lymphomas and solid organ tumors. because it is difficult to characterize and define. Various indirect definitions proposed include a sensation which provokes the desire to scratch or an uneasy sensation of 2.
    [Show full text]
  • Dermatologia 2021;96(4):397---407
    Anais Brasileiros de Dermatologia 2021;96(4):397---407 Anais Brasileiros de Dermatologia www.anaisdedermatologia.org.br CONTINUING MEDICAL EDUCATION Phototherapyଝ,ଝଝ ∗ Norami de Moura Barros , Lissiê Lunardi Sbroglio , Maria de Oliveira Buffara , Jessica Lana Conceic¸ão e Silva Baka , Allen de Souza Pessoa , Luna Azulay-Abulafia Department of Dermatology, Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil Received 3 December 2019; accepted 2 March 2021 Available online 2 April 2021 Abstract Of all the therapeutic options available in Dermatology, few of them have the his- KEYWORDS tory, effectiveness, and safety of phototherapy. Heliotherapy, NB-UVB, PUVA, and UVA1 are Phototherapy; currently the most common types of phototherapy used. Although psoriasis is the most frequent PUVA therapy; indication, it is used for atopic dermatitis, vitiligo, cutaneous T-cell lymphoma, and cutaneous Ultraviolet therapy sclerosis, among others. Before indicating phototherapy, a complete patient assessment should be performed. Possible contraindications should be actively searched for and it is essential to assess whether the patient can come to the treatment center at least twice a week. One of the main method limitations is the difficulty that patients have to attend the sessions. This therapy usually occurs in association with other treatments: topical or systemic medications. Maintaining the regular monitoring of the patient is essential to identify and treat possible adverse effects. Phototherapy is recognized for its benefits and should be considered whenever possible. © 2021 Sociedade Brasileira de Dermatologia. Published by Elsevier Espana,˜ S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
    [Show full text]
  • Report from the Inaugural Australian Pruritus Symposium, Sydney, Australia, August 10, 2013
    Acta Derm Venereol 2014; 94: 123 LETTER TO THE EDITOR Report from the Inaugural Australian Pruritus Symposium, Sydney, Australia, August 10, 2013 Frank Brennan1 and Dedee F. Murrell2* 1Palliative Medicine, Calvary Hospital, 91 Rocky Point Road, and 2Department of Dermatology, St George Hospital, University of New South Wales, Gray St, Kogarah, Sydney, NSW 2217 Australia. *E-mail: [email protected] Accepted Aug 28, 2013; Epub ahead of print Oct 24, 2013 Sir, on the mechanisms and management of opioid-induced The inaugural Australian symposium on pruritus was itch. Frank Brennan spoke on uraemic pruritus, Paul Gray, convened at St George Hospital, Sydney on August 10, a Pain Specialist with a particular interest in burns spoke 2013. The co-conveners were Professor Dedee Murrell, on the phenomenon of post-burns pruritus and Craig Le- Executive Vice President of the International Society of wis, Medical Oncologist surveyed the symptom of itch Dermatology (ISD) and Dr Frank Brennan, Palliative and its management in cancer medicine. Medicine Physician. The impetus behind the symposium A feature of the day was an interview with a patient was the recognition of two facts. Firstly, the significant in front of the symposium participants. The patient developments in the understanding of the pathophysio- presented with a challenging combination of pruritus logy of pruritus in recent years and, secondly, the paucity secondary to a life-long history of atopy and, in later of education and understanding by colleagues across years, uraemic pruritus. Connie Katelaris surveyed the multiple disciplines of those developments. Given that history and immunological results of the patient and the symptom of pruritus manifests in many diseases the made clinical recommendations.
    [Show full text]
  • European Guideline Chronic Pruritus Final Version
    EDF-Guidelines for Chronic Pruritus In cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Européenne des Médecins Spécialistes (UEMS) E Weisshaar1, JC Szepietowski2, U Darsow3, L Misery4, J Wallengren5, T Mettang6, U Gieler7, T Lotti8, J Lambert9, P Maisel10, M Streit11, M Greaves12, A Carmichael13, E Tschachler14, J Ring3, S Ständer15 University Hospital Heidelberg, Clinical Social Medicine, Environmental and Occupational Dermatology, Germany1, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Poland2, Department of Dermatology and Allergy Biederstein, Technical University Munich, Germany3, Department of Dermatology, University Hospital Brest, France4, Department of Dermatology, Lund University, Sweden5, German Clinic for Diagnostics, Nephrology, Wiesbaden, Germany6, Department of Psychosomatic Dermatology, Clinic for Psychosomatic Medicine, University of Giessen, Germany7, Department of Dermatology, University of Florence, Italy8, Department of Dermatology, University of Antwerpen, Belgium9, Department of General Medicine, University Hospital Muenster, Germany10, Department of Dermatology, Kantonsspital Aarau, Switzerland11, Department of Dermatology, St. Thomas Hospital Lambeth, London, UK12, Department of Dermatology, James Cook University Hospital Middlesbrough, UK13, Department of Dermatology, Medical University Vienna, Austria14, Department of Dermatology, Competence Center for Pruritus, University Hospital Muenster, Germany15 Corresponding author: Elke Weisshaar
    [Show full text]
  • Module Test № 1 on Dermatology
    THE MINISTRY OF HEALTHCARE OF THE RUSSIAN FEDERATION FEDERAL STATE BUDGETARY EDUCATIONAL INSTITUTION OF HIGHER PROFESSIONAL EDUCATION PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY DEPARTMENT OF DERMATOVENEROLOGY Gaydina T.A., Dvornikov A.S., Skripkina P.A., Nazhmutdinova D.K., Heydar S.A., Arutunyan G.B., Pashinyan A.G. MODULE TEST №1 ON DERMATOLOGY FOR STUDENTS OF INSTITUTES OF HIGHER MEDICAL EDUCATION ON SPECIALTY THERAPEUTIC FACULTY DEPARTMENT OF DERMATOVENEROLOGY Moscow 2016 ISBN УДК ББК A21 Module test №1 on Dermatology for students of institutes of high medical education on specialty «Therapeutic faculty» department of dermatovenerology: manual for students for self-training//FSBEI HPE “Pirogov RNRMU” of the ministry of healthcare of the russian federation, M.: (publisher) 2016, 144 p. The manual is a part of teaching-methods on Dermatovenerology. It contains tests on Dermatology on the topics of practical sessions requiring single or multiple choice anser. The manual can be used to develop skills of students during practical sessions. It also can be used in the electronic version at testing for knowledge. The manual is compiled according to FSES on specialty “therapeutic faculty”, working programs on dermatovenerology. The manual is intended for foreign students of 3-4 courses on specialty “therapeutic faculty” and physicians for professional retraining. Authors: Gaydina T.A. – candidate of medical science, assistant of dermatovenerology department of therapeutic faculty Pirogov RNRMU Dvornikov A.S. – M.D., professor of dermatovenerology department of therapeutic faculty Pirogov RNRMU Skripkina P.A. – candidate of medical science, assistant professor of dermatovenerology department of therapeutic faculty Pirogov RNRMU Nazhmutdinova D.K. – candidate of medical science, assistant professor of dermatovenerology department of therapeutic faculty Pirogov RNRMU Heydar S.A.
    [Show full text]
  • Pruritus: Scratching the Surface
    Pruritus: Scratching the surface Iris Ale, MD Director Allergy Unit, University Hospital Professor of Dermatology Republic University, Uruguay Member of the ICDRG ITCH • defined as an “unpleasant sensation of the skin leading to the desire to scratch” -- Samuel Hafenreffer (1660) • The definition offered by the German physician Samuel Hafenreffer in 1660 has yet to be improved upon. • However, it turns out that itch is, indeed, inseparable from the desire to scratch. Savin JA. How should we define itching? J Am Acad Dermatol. 1998;39(2 Pt 1):268-9. Pruritus • “Scratching is one of nature’s sweetest gratifications, and the one nearest to hand….” -- Michel de Montaigne (1553) “…..But repentance follows too annoyingly close at its heels.” The Essays of Montaigne Itch has been ranked, by scientific and artistic observers alike, among the most distressing physical sensations one can experience: In Dante’s Inferno, falsifiers were punished by “the burning rage / of fierce itching that nothing could relieve” Pruritus and body defence • Pruritus fulfils an essential part of the innate defence mechanism of the body. • Next to pain, itch may serve as an alarm system to remove possibly damaging or harming substances from the skin. • Itch, and the accompanying scratch reflex, evolved in order to protect us from such dangers as malaria, yellow fever, and dengue, transmitted by mosquitoes, typhus-bearing lice, plague-bearing fleas • However, chronic itch lost this function. Chronic Pruritus • Chronic pruritus is a common and distressing symptom, that is associated with a variety of skin conditions and systemic diseases • It usually has a dramatic impact on the quality of life of the affected individuals Chronic Pruritus • Despite being the major symptom associated with skin disease, our understanding of the pathogenesis of most types of itch is limited, and current therapies are often inadequate.
    [Show full text]
  • Update of the Guideline on Chronic Pruritus
    Update of the Guideline on Chronic Pruritus Developed by the Guideline Subcommittee “Chronic Pruritus” of the European Dermatology Forum Subcommittee Members: Prof. Dr. Elke Weisshaar, Heidelberg (Germany) Prof. Dr. Sonja Ständer, Münster (Germany) Prof. Dr. Erwin Tschachler, Wien (Austria) Prof. Dr. Torello Lotti, Florence (Italy) Prof. Dr. Johannes Ring, Munich (Germany) Prof. Dr. Laurent Misery, Brest (France) Dr. Markus Streit, Aarau (Switzerland) Prof. Dr. Thomas Mettang, Wiesbaden (Germany) Prof. Dr. Jacek Szepietowski, Wroclaw (Poland) Prof. Dr. Joanna Wallengren, Lund (Sweden) Dr. Peter Maisel, Münster (Germany) Prof. Dr. Uwe Gieler, Gießen (Germany) Prof. Dr. Malcolm Greaves (Singapore) Prof. Dr. Ulf Darsow, Munich (Germany) Prof. Dr. Julien Lambert, Antwerp (Belgium) Members of EDF Guideline Committee: Prof. Dr. Werner Aberer, Graz (Austria) Prof. Dr. Dieter Metze, Münster (Germany) Prof. Dr. Martine Bagot, Paris (France) Dr. Kai Munte, Rotterdam (Netherlands) Prof. Dr. Nicole Basset-Seguin, Paris (France) Prof. Dr. Gilian Murphy, Dublin (Ireland) Prof. Dr. Ulrike Blume-Peytavi, Berlin (Germany) Prof. Dr. Martino Neumann, Rotterdam (Netherlands) Prof. Dr. Lasse Braathen, Bern (Switzerland) Prof. Dr. Tony Ormerod, Aberdeen (UK) Prof. Dr. Sergio Chimenti, Rome (Italy) Prof. Dr. Mauro Picardo, Rome (Italy) Prof. Dr. Alexander Enk, Heidelberg (Germany) Prof. Dr. Johannes Ring, Munich (Germany) Prof. Dr. Claudio Feliciani, Rome (Italy) Prof. Dr. Annamari Ranki, Helsinki (Finland) Prof. Dr. Claus Garbe, Tübingen (Germany) Prof. Dr. Berthold Rzany, Berlin (Germany) Prof. Dr. Harald Gollnick, Magdeburg (Germany) Prof. Dr. Rudolf Stadler, Minden (Germany) Prof. Dr. Gerd Gross, Rostock (Germany) Prof. Dr. Sonja Ständer, Münster (Germany) Prof. Dr. Vladimir Hegyi, Bratislava (Slovakia) Prof. Dr. Eggert Stockfleth, Berlin (Germany) Prof. Dr.
    [Show full text]
  • PC22 Doc. 22.1 Annex (In English Only / Únicamente En Inglés / Seulement En Anglais)
    Original language: English PC22 Doc. 22.1 Annex (in English only / únicamente en inglés / seulement en anglais) Quick scan of Orchidaceae species in European commerce as components of cosmetic, food and medicinal products Prepared by Josef A. Brinckmann Sebastopol, California, 95472 USA Commissioned by Federal Food Safety and Veterinary Office FSVO CITES Management Authorithy of Switzerland and Lichtenstein 2014 PC22 Doc 22.1 – p. 1 Contents Abbreviations and Acronyms ........................................................................................................................ 7 Executive Summary ...................................................................................................................................... 8 Information about the Databases Used ...................................................................................................... 11 1. Anoectochilus formosanus .................................................................................................................. 13 1.1. Countries of origin ................................................................................................................. 13 1.2. Commercially traded forms ................................................................................................... 13 1.2.1. Anoectochilus Formosanus Cell Culture Extract (CosIng) ............................................ 13 1.2.2. Anoectochilus Formosanus Extract (CosIng) ................................................................ 13 1.3. Selected finished
    [Show full text]
  • Abstracts from the 9Th World Congress on Itch October 15–17, 2017
    ISSN 0001-5555 ActaDV Volume 97 2017 SEPTEMBER, No. 8 ADVANCES IN DERMATOLOGY AND VENEREOLOGY A Non-profit International Journal for Interdisciplinary Skin Research, Clinical and Experimental Dermatology and Sexually Transmitted Diseases Abstracts from the 9th World Congress on Itch October 15–17, 2017 Official Journal of - European Society for Dermatology and Wroclaw, Poland Psychiatry Affiliated with - The International Forum for the Study of Itch Immediate Open Access Acta Dermato-Venereologica www.medicaljournals.se/adv Abstracts from the 9th World Congress on Itch DV cta A enereologica V Organizing Committee Scientific Committee ermato- Congress President: Jacek C Szepietowski (Wroclaw, Poland) Jeffrey D. Bernhard (Massachusetts, USA) D Congress Secretary General: Adam Reich (Rzeszów, Poland) Earl Carstens (Davis, USA) Congress Secretary: Edyta Lelonek (Wroclaw, Poland) Toshiya Ebata (Tokyo, Japan) cta Alan Fleischer (Lexington, USA) A IFSI President: Earl Carstens (Davis, USA) IFSI Vice President: Elke Weisshaar (Heidelberg, Germany) Ichiro Katayama (Osaka, Japan) Ethan Lerner (Boston, USA) Staff members of the Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland Thomas Mettang (Wiesbaden, Germany) Martin Schmelz (Mannheim, Germany) Sonja Ständer (Münster, Germany) DV Jacek C. Szepietowski (Wroclaw, Poland) cta Kenji Takamori (Tokyo, Japan) A Elke Weisshaar (Heidelberg, Germany) Gil Yosipovitch (Miami, USA) Contents of this Abstract book Program 1000 Abstracts: Lecture Abstracts 1008 Poster Abstracts 1035 Author Index 1059 dvances in dermatology and venereology A www.medicaljournals.se/acta doi: 10.2340/00015555-2773 Journal Compilation © 2017 Acta Dermato-Venereologica. Acta Derm Venereol 2017; 97: 999–1060 1000 9th World Congress of Itch Sunday, October 15, 2017 Abstract # 1:30-3:30 PM IFSI Board meeting DV 5:00-5:20 PM OPENING CEREMONY 5:00-5:10 PM Opening remarks cta Jacek C.
    [Show full text]
  • Pruritus Ani (Itchy Bottom)
    PRURITUS ANI (ITCHY BOTTOM) What is pruritus ani? Pruritus ani means a chronic (persistent) itchy feeling around the anus. The main symptom is an urge to scratch your anus which is difficult to resist. The urge to scratch may occur at any time. However, it tends to be more common after you have been to the toilet to pass faeces, and at night (particularly just before falling asleep). The itch may be made worse by heat, wool, moisture, leaking, soiling, stress, and anxiety. About 1 in 20 people develop pruritus ani at some stage. It is common in both adults and children. What causes pruritus ani? Pruritus ani is a symptom, not a final diagnosis. Various conditions may cause pruritus ani. However, in many cases the cause is not clear. This is called ‘idiopathic pruritus ani’, which means ‘itchy anus of unknown cause’. Known causes of pruritus ani There are various causes which include the following: Inflamed anal skin is a common cause (a localised dermatitis). The inflammation is usually due to the skin ‘reacting’ to small amounts of faeces (sometimes called stools or motions) left on the skin, and/or to sweat and moisture around the anus. Young children who may not wipe themselves properly, adults with sweaty jobs, and adults with a lot of hair round the anus may be especially prone to this. Thrush and fungal infections. These germs like it best in moist, warm, airless areas, such as around the anus. Thrush is more common in people with diabetes. Other infections such as scabies, herpes, anal warts and some other sexually transmitted diseases can cause itch around the anus.
    [Show full text]